

Final Closing of Drug Discovery Gateway Fund (LP)

6th April, 2021

Whiz Partners Inc. (Minato-ku, Tokyo) is pleased to announce the final closing of Drug Discovery Gateway Fund (LLP) (“DDGF”) on March 31st. The fund is invested by institutional investors and business companies, and total fund size is 18 billion JPY.

DDGF Fund is mainly focusing on its investment to Axcelead, Inc. (“Axcelead”), a holding company. Axcelead Drug Discovery Partners, Inc (“ADDP”), a spin-off company from Takeda Pharmaceutical Co., Ltd. (“Takeda”), is a key subsidiary of Axcelead Group.

ADDP is the first comprehensive integrated drug discovery solutions provider in Japan, having succeeded significant portions of the drug discovery research function of Takeda and started its business in July 1, 2017. Since then, ADDP have developed partnerships with more than 100 customers which includes the most of drug discovery type pharmaceutical companies in Japan. This indicates that ADDP succeed to establish a totally new “Drug Discovery Platform Business” in Japan.

Axcelead is expanding its drug discovery platform, including medical devices, contract development and manufacturing organization (CDMO) for a new therapeutic modality, and drug discovery technology utilized artificial intelligence.

Axcelead continue to lead the market with the new concept of “Drug Discovery Platform Business” and aim to IPO after 2023 3Q.

Company Name	Axcelead, Inc. (https://www.axcelead-hd.com/)
CEO	President and CEO: Tomoyuki Fujisawa
Shareholder	Shareholder – Drug Discovery Gateway Fund LP (100%)
Subsidiary	Axcelead Drug Discovery Partners, Inc., etc.
Founded	April 27, 2017: spun-off from Takeda

	April 1, 2020 : Incorporation-type Company Split
Location	26-1, Muraoka-Higashi 2-chome Fujisawa, Kanagawa 251-0012, Japan
Scope of business	Holding company having Axcelead Drug Discovery Partners, Inc. as its key subsidiary
Financial month	March
Capital	100 million yen

Company introduction in Youtube https://youtu.be/Bj83Q_i7Bfw

Fund Information <http://www.whizp.com/e/fund/>

Portfolio companies

Name	Business description	Website
Axcelead, Inc.	Holding company having Axcelead Drug Discovery Partners, Inc. as its key subsidiary	https://www.axcelead-hd.com/
PassPort Technologies, Inc.	Transdermal formulation and medical device development of "PassPort System"	https://passport-tech.com/
Sylvian, Inc.	Development of trehalose therapeutic agent for vascular spasm after subarachnoid hemorrhage	-
ActualEyes Inc	R&D of cell-therapy and pharmacological treatments for corneal endothelial diseases	https://www.actualeyes.co.jp/
caresyntax Corporation	Automation and AI for the operating Room, Analysis, research, and consulting	https://caresyntax.com

	service on various medical data	
Capital Medica Co., Ltd	Operation and management consulting for hospitals, medical related service solutions, Service for the Elderly	https://capimedi.com/